在我看来，新基准的制定将带来诸多好处，尤其是股票分析师，他们可以考虑根据药品获取基金会的研究成果来调整他们所推荐的股票。
In my view, the new benchmark will have many benefits, not least for equity analysts who might consider adjusting their stock recommendations on the basis of the AMF’s findings.